{"transactions":[{"id":4636927,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-10-07T20:02:29.000Z","date":"2026-10-05","kind":"tax_withholding","planned":false,"acquired":false,"shares":2693,"price":4.38,"value":11795.34,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units previously granted."}],"balance_after":1074990,"source":{"system":"sec-edgar","filing":"0001628280-26-065323","document":"wk-form4_1791403347.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1826667/000162828026065323/wk-form4_1791403347.xml","form_type":"4"}},{"id":715251,"issuer":{"id":4685,"kind":"organization","name":"Absci Corp","symbol":"ABSI"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-06T20:06:13.000Z","date":"2026-06-30","kind":"purchase","planned":false,"acquired":true,"shares":12900,"price":11.54,"value":148866.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Open market purchase of shares in accordance with Issuer's trading policies."}],"balance_after":21300,"source":{"system":"sec-edgar","filing":"0001672688-26-000124","document":"wk-form4_1783368371.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672688/000167268826000124/wk-form4_1783368371.xml","form_type":"4"}},{"id":720995,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-07-01T20:04:47.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":3990,"price":3.87,"value":15441.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3."}],"balance_after":1077683,"source":{"system":"sec-edgar","filing":"0001628280-26-046519","document":"wk-form4_1782936285.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000162828026046519/wk-form4_1782936285.xml","form_type":"4"}},{"id":720994,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-07-01T20:03:32.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":2100,"price":4.38,"value":9198.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3."}],"balance_after":1023826,"source":{"system":"sec-edgar","filing":"0001628280-26-046511","document":"wk-form5_1782936210.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000162828026046511/wk-form5_1782936210.xml","form_type":"5"}},{"id":720993,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-07-01T20:03:32.000Z","date":"2025-06-30","kind":"grant","planned":false,"acquired":true,"shares":2848,"price":4.23,"value":12047.04,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3."}],"balance_after":596726,"source":{"system":"sec-edgar","filing":"0001628280-26-046511","document":"wk-form5_1782936210.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000162828026046511/wk-form5_1782936210.xml","form_type":"5"}},{"id":720992,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-07-01T20:03:32.000Z","date":"2024-12-31","kind":"grant","planned":false,"acquired":true,"shares":3530,"price":4.26,"value":15037.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3."}],"balance_after":513207,"source":{"system":"sec-edgar","filing":"0001628280-26-046511","document":"wk-form5_1782936210.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000162828026046511/wk-form5_1782936210.xml","form_type":"5"}},{"id":737807,"issuer":{"id":4685,"kind":"organization","name":"Absci Corp","symbol":"ABSI"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-16T00:40:31.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":33200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option vest and become exercisable in full on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such date."}],"balance_after":33200,"derivative":{"exercise_price":7.34,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":33200},"source":{"system":"sec-edgar","filing":"0001672688-26-000116","document":"wk-form4a_1781570428.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672688/000167268826000116/wk-form4a_1781570428.xml","form_type":"4/A","original_submission_date":"2026-06-08"}},{"id":737806,"issuer":{"id":4685,"kind":"organization","name":"Absci Corp","symbol":"ABSI"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-16T00:40:31.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":8400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") issued under the Absci Corporation 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest and be settled in full on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such date."}],"balance_after":8400,"source":{"system":"sec-edgar","filing":"0001672688-26-000116","document":"wk-form4a_1781570428.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672688/000167268826000116/wk-form4a_1781570428.xml","form_type":"4/A","original_submission_date":"2026-06-08"}},{"id":746163,"issuer":{"id":4685,"kind":"organization","name":"Absci Corp","symbol":"ABSI"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-09T01:59:15.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":39800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option vest and become exercisable in full on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such date."}],"balance_after":39800,"derivative":{"exercise_price":7.34,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":39800},"source":{"system":"sec-edgar","filing":"0001470831-26-000526","document":"wk-form4_1780970353.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672688/000147083126000526/wk-form4_1780970353.xml","form_type":"4"}},{"id":746162,"issuer":{"id":4685,"kind":"organization","name":"Absci Corp","symbol":"ABSI"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-09T01:59:15.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":10100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") issued under the Absci Corporation 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest and be settled in full on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such date."}],"balance_after":10100,"source":{"system":"sec-edgar","filing":"0001470831-26-000526","document":"wk-form4_1780970353.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672688/000147083126000526/wk-form4_1780970353.xml","form_type":"4"}},{"id":749457,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2026-06-04T22:30:04.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in full on the one year anniversary of the date of grant."}],"balance_after":35000,"derivative":{"exercise_price":8.77,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001193125-26-257897","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526257897/ownership.xml","form_type":"4"}},{"id":774789,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-05-18T20:42:30.000Z","date":"2026-05-15","kind":"purchase","planned":false,"acquired":true,"shares":39682,"price":2.59,"value":102776.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person's purchase of common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 39,682 shares at a weighted average price of $2.59, with the Reporting Person's sales of 4,358 shares of common stock at a price per share of $4.13 on March 11, 2026 and of 15,944 shares of common stock at a price per share of $3.85. The prior sales represented shares sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person, and did not represent discretionary sales by the Reporting Person. The Reporting Person paid $27,573.70 to the Issuer, representing the full amount of profit realized in connection with the short-swing transaction."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.48 to $2.62 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":1065215,"source":{"system":"sec-edgar","filing":"0001628280-26-035994","document":"wk-form4_1779136946.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000162828026035994/wk-form4_1779136946.xml","form_type":"4"}},{"id":832272,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-03-20T20:25:26.000Z","date":"2026-03-17","kind":"sale","planned":false,"acquired":false,"shares":15944,"price":3.85,"value":61384.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the reporting person. This transaction does not represent a discretionary sale by the reporting person."}],"balance_after":752987,"source":{"system":"sec-edgar","filing":"0001628280-26-020186","document":"wk-form4_1774038323.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000162828026020186/wk-form4_1774038323.xml","form_type":"4"}},{"id":832271,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-03-20T20:25:26.000Z","date":"2026-03-11","kind":"sale","planned":false,"acquired":false,"shares":4358,"price":4.13,"value":17998.54,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the reporting person. This transaction does not represent a discretionary sale by the reporting person."}],"balance_after":768931,"source":{"system":"sec-edgar","filing":"0001628280-26-020186","document":"wk-form4_1774038323.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000162828026020186/wk-form4_1774038323.xml","form_type":"4"}},{"id":887896,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-02-23T21:08:06.000Z","date":"2026-02-23","kind":"purchase","planned":false,"acquired":true,"shares":30487,"price":4.1,"value":124996.7,"ownership":{"direct":true},"balance_after":773289,"source":{"system":"sec-edgar","filing":"0001628280-26-010603","document":"wk-form4_1771880883.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000162828026010603/wk-form4_1771880883.xml","form_type":"4"}},{"id":988560,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-11-25T20:55:07.000Z","date":"2025-11-24","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of November 24, 2025 (the \"VCD\"), and 1/36th of the remaining shares\nshall vest each month thereafter on the same day of the month as the VCD (or if there is no corresponding day, on the last day of the month), subject to continued employment through the respective vesting date."}],"balance_after":1578182,"derivative":{"exercise_price":5.55,"expiration_date":"2035-11-23","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001410289-25-000006","document":"wk-form4_1764104104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000141028925000006/wk-form4_1764104104.xml","form_type":"4"}},{"id":988559,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2025-11-25T20:55:07.000Z","date":"2025-11-24","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the granting of PSUs upon achieving or exceeding $75 million of revenue over any 12 consecutive calendar month period ending on or before December 31, 2027. 150,000 PSUs vest immediately upon achieving the performance requirement and 150,000 PSUs vest on the one-year anniversary of achieving the performance requirement, subject to the continued employment through each respective vesting date."}],"balance_after":742802,"source":{"system":"sec-edgar","filing":"0001410289-25-000006","document":"wk-form4_1764104104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000141028925000006/wk-form4_1764104104.xml","form_type":"4"}},{"id":988558,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2025-11-25T20:55:07.000Z","date":"2025-11-24","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents grant of restricted stock units (the \"RSU Award\") payable solely in common stock of the Issuer. The shares subject to the RSU Award vest in four equal annual installments commencing on November 24, 2025, subject to continued employment through the respective vesting date."}],"balance_after":442802,"source":{"system":"sec-edgar","filing":"0001410289-25-000006","document":"wk-form4_1764104104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000141028925000006/wk-form4_1764104104.xml","form_type":"4"}},{"id":988557,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2025-11-25T20:55:07.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the granting of Performance Stock Units (PSUs) upon achieving or exceeding $50 million of revenue over any 12 consecutive calendar month period ending on or before February 28, 2027. The PSUs vest immediately upon achieving the performance requirement, subject to the continued employment through each respective vesting date."}],"balance_after":317802,"source":{"system":"sec-edgar","filing":"0001410289-25-000006","document":"wk-form4_1764104104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000141028925000006/wk-form4_1764104104.xml","form_type":"4"}},{"id":1089985,"issuer":{"id":4685,"kind":"organization","name":"Absci Corp","symbol":"ABSI"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-09T20:46:43.000Z","date":"2025-07-07","kind":"grant","planned":false,"acquired":true,"shares":178400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option vest and become exercisable in 36 approximately equal monthly installments from July 7, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":178400,"derivative":{"exercise_price":2.58,"expiration_date":"2035-07-06","underlying":"Common Stock","underlying_shares":178400},"source":{"system":"sec-edgar","filing":"0001628280-25-034662","document":"wk-form4_1752093997.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672688/000162828025034662/wk-form4_1752093997.xml","form_type":"4"}},{"id":1119465,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2025-06-06T20:05:05.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":28500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in full on the one year anniversary of the date of grant."}],"balance_after":28500,"derivative":{"exercise_price":6.57,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":28500},"source":{"system":"sec-edgar","filing":"0000950170-25-083035","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000095017025083035/ownership.xml","form_type":"4"}},{"id":1259578,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO AND PRESIDENT"}}],"security":"Common Stock","published_at":"2025-02-19T22:41:47.000Z","date":"2025-02-18","kind":"grant","planned":false,"acquired":true,"shares":21089,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units (the \"RSU Award\") payable solely in common stock of the Issuer. The shares subject to the RSU Award shall vest on February 13, 2026, subject to the Reporting Person's continued service with the Issuer on such vesting date."}],"balance_after":465348,"source":{"system":"sec-edgar","filing":"0001415889-25-004682","document":"form4-02192025_100243.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000141588925004682/form4-02192025_100243.xml","form_type":"4"}},{"id":1289350,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO AND PRESIDENT"}}],"security":"Common Stock","published_at":"2025-01-31T22:54:39.000Z","date":"2025-01-30","kind":"purchase","planned":false,"acquired":true,"shares":5010,"price":5.28,"value":26452.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.15 to $5.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":444259,"source":{"system":"sec-edgar","filing":"0001415889-25-002536","document":"form4-01312025_100135.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000141588925002536/form4-01312025_100135.xml","form_type":"4"}},{"id":1289349,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO AND PRESIDENT"}}],"security":"Common Stock","published_at":"2025-01-31T22:54:39.000Z","date":"2025-01-29","kind":"purchase","planned":false,"acquired":true,"shares":5030,"price":5.03,"value":25300.9,"ownership":{"direct":true},"balance_after":439249,"source":{"system":"sec-edgar","filing":"0001415889-25-002536","document":"form4-01312025_100135.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000141588925002536/form4-01312025_100135.xml","form_type":"4"}},{"id":1291761,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO AND PRESIDENT"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-01-29T23:15:05.000Z","date":"2025-01-27","kind":"grant","planned":false,"acquired":true,"shares":240000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of January 1, 2025 (the \"VCD\"), and 1/36th of the remaining shares shall vest each month thereafter on the same day of the month as the VCD (or if there is no corresponding day, on the last day of the month), subject to the Reporting Person's continuous service with the Issuer on each respective vesting date."}],"balance_after":240000,"derivative":{"exercise_price":5.3,"expiration_date":"2035-01-26","underlying":"Common Stock","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0001415889-25-002292","document":"form4-01292025_110101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000141588925002292/form4-01292025_110101.xml","form_type":"4"}},{"id":1291760,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO AND PRESIDENT"}}],"security":"Common Stock","published_at":"2025-01-29T23:15:05.000Z","date":"2025-01-28","kind":"purchase","planned":false,"acquired":true,"shares":4716,"price":5.12,"value":24145.92,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.03 to $5.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":434219,"source":{"system":"sec-edgar","filing":"0001415889-25-002292","document":"form4-01292025_110101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000141588925002292/form4-01292025_110101.xml","form_type":"4"}},{"id":1291759,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO AND PRESIDENT"}}],"security":"Common Stock","published_at":"2025-01-29T23:15:05.000Z","date":"2025-01-27","kind":"purchase","planned":false,"acquired":true,"shares":4826,"price":5.42,"value":26156.92,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.25 to $5.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":429503,"source":{"system":"sec-edgar","filing":"0001415889-25-002292","document":"form4-01292025_110101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000141588925002292/form4-01292025_110101.xml","form_type":"4"}},{"id":1291758,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO AND PRESIDENT"}}],"security":"Common Stock","published_at":"2025-01-29T23:15:05.000Z","date":"2025-01-27","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units (the \"RSU Award\") payable solely in common stock of the Issuer. The shares subject to the RSU Award vest in four equal annual installments commencing on January 1, 2025, subject to the Reporting Person's continued service with the Issuer on each respective vesting date."}],"balance_after":424677,"source":{"system":"sec-edgar","filing":"0001415889-25-002292","document":"form4-01292025_110101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000141588925002292/form4-01292025_110101.xml","form_type":"4"}},{"id":1407576,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO AND PRESIDENT"}}],"security":"Common Stock","published_at":"2024-09-13T21:43:14.000Z","date":"2024-09-13","kind":"purchase","planned":false,"acquired":true,"shares":6000,"price":5,"value":30000.0,"ownership":{"direct":true},"balance_after":384677,"source":{"system":"sec-edgar","filing":"0001415889-24-023390","document":"form4-09132024_090910.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000141588924023390/form4-09132024_090910.xml","form_type":"4"}},{"id":1407575,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO AND PRESIDENT"}}],"security":"Common Stock","published_at":"2024-09-13T21:43:14.000Z","date":"2024-09-13","kind":"purchase","planned":false,"acquired":true,"shares":1295,"price":4.83,"value":6254.85,"ownership":{"direct":true},"balance_after":378677,"source":{"system":"sec-edgar","filing":"0001415889-24-023390","document":"form4-09132024_090910.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000141588924023390/form4-09132024_090910.xml","form_type":"4"}},{"id":1407574,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO AND PRESIDENT"}}],"security":"Common Stock","published_at":"2024-09-13T21:43:14.000Z","date":"2024-09-12","kind":"purchase","planned":false,"acquired":true,"shares":7520,"price":5.2,"value":39104.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.05 to $5.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":377382,"source":{"system":"sec-edgar","filing":"0001415889-24-023390","document":"form4-09132024_090910.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000141588924023390/form4-09132024_090910.xml","form_type":"4"}},{"id":1408528,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO AND PRESIDENT"}}],"security":"Common Stock","published_at":"2024-09-12T23:06:21.000Z","date":"2024-09-10","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":4.97,"value":24850.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $4.91 to $4.99, inclusive.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":369862,"source":{"system":"sec-edgar","filing":"0001415889-24-023320","document":"form4-09122024_110917.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000141588924023320/form4-09122024_110917.xml","form_type":"4"}},{"id":1472189,"issuer":{"id":83618,"kind":"organization","name":"Omega Therapeutics, Inc.","symbol":"OMGA"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-21T16:20:13.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":2.2,"expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000950170-24-076267","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850838/000095017024076267/ownership.xml","form_type":"4"}},{"id":1486607,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2024-06-07T20:30:10.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in full on the one year anniversary of the date of grant."}],"balance_after":26000,"derivative":{"exercise_price":21.79,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0000950170-24-070702","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000095017024070702/ownership.xml","form_type":"4"}},{"id":1642905,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO AND PRESIDENT"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-02-14T23:44:45.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":288750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of February 13, 2024, and 1/36th of the remaining shares shall vest each month thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date."}],"balance_after":288750,"derivative":{"exercise_price":9.4,"expiration_date":"2034-02-12","underlying":"Common Stock","underlying_shares":288750},"source":{"system":"sec-edgar","filing":"0001415889-24-003821","document":"form4-02142024_110233.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000141588924003821/form4-02142024_110233.xml","form_type":"4"}},{"id":1642904,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO AND PRESIDENT"}}],"security":"Common Stock","published_at":"2024-02-14T23:44:45.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":84899,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units (the \"RSU Award\") payable solely in common stock of the Issuer. The shares subject to the RSU Award vest in four equal annual installments commencing on February 13, 2024, subject to the Reporting Person's continued service with the Issuer on each respective vesting date."}],"balance_after":364862,"source":{"system":"sec-edgar","filing":"0001415889-24-003821","document":"form4-02142024_110233.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000141588924003821/form4-02142024_110233.xml","form_type":"4"}},{"id":1807267,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-08-15T20:48:12.000Z","date":"2023-08-14","kind":"grant","planned":false,"acquired":true,"shares":172500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date of August 10, 2023, and 1/36th of the remaining shares shall vest each month thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date."}],"balance_after":172500,"derivative":{"exercise_price":11.51,"expiration_date":"2033-08-13","underlying":"Common Stock","underlying_shares":172500},"source":{"system":"sec-edgar","filing":"0001209191-23-045877","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000120919123045877/doc4.xml","form_type":"4"}},{"id":1851915,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T20:00:28.000Z","date":"2023-06-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,.. (Continued in Footnote 3)"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,.. (Continued in Footnote 3)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."}],"balance_after":0,"derivative":{"exercise_price":29.02,"expiration_date":"2032-05-18","underlying":"Common Stock","underlying_shares":20500},"source":{"system":"sec-edgar","filing":"0000899243-23-015755","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000089924323015755/doc4.xml","form_type":"4"}},{"id":1851914,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T20:00:28.000Z","date":"2023-06-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":40000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,.. (Continued in Footnote 3)"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,.. (Continued in Footnote 3)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."}],"balance_after":0,"derivative":{"exercise_price":19,"expiration_date":"2031-03-10","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000899243-23-015755","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000089924323015755/doc4.xml","form_type":"4"}},{"id":1851913,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-16T20:00:28.000Z","date":"2023-06-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2071,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,.. (Continued in Footnote 3)"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-015755","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000089924323015755/doc4.xml","form_type":"4"}},{"id":1860836,"issuer":{"id":83618,"kind":"organization","name":"Omega Therapeutics, Inc.","symbol":"OMGA"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-09T16:05:08.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":18118,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date."}],"balance_after":18118,"derivative":{"exercise_price":8.39,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":18118},"source":{"system":"sec-edgar","filing":"0000899243-23-015147","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850838/000089924323015147/doc4.xml","form_type":"4"}},{"id":1869498,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2023-06-02T21:02:46.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in full on the one year anniversary of the date of grant."}],"balance_after":26000,"derivative":{"exercise_price":13.32,"expiration_date":"2033-05-30","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001209191-23-033888","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000120919123033888/doc4.xml","form_type":"4"}},{"id":1884389,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-19T21:47:10.000Z","date":"2023-05-19","kind":"grant","planned":false,"acquired":true,"shares":2071,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Award of restricted stock units (\"RSUs\") granted under the Issuer's 2021 Incentive Award Plan (the \"2021 Plan\").  Each RSU entitles the Reporting Person to receive one share of Issuer common stock upon vesting.  The RSUs shall vest in full upon the earlier to occur of (i) the first anniversary of the date of grant, (ii) the Issuer's next occurring annual meeting of stockholders, or (iii) a Change of Control (as defined in the 2021 Plan), subject to the Reporting Person's continued service with the Issuer on such vesting date."}],"balance_after":2071,"source":{"system":"sec-edgar","filing":"0001209191-23-031193","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000120919123031193/doc4.xml","form_type":"4"}},{"id":2222963,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2022-06-23T20:49:47.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in full on the one year anniversary of the date of grant."}],"balance_after":23000,"derivative":{"exercise_price":14.84,"expiration_date":"2032-06-20","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001209191-22-038926","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000120919122038926/doc4.xml","form_type":"4"}},{"id":2236322,"issuer":{"id":83618,"kind":"organization","name":"Omega Therapeutics, Inc.","symbol":"OMGA"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (Right to Buy)","published_at":"2022-06-10T16:10:21.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":18118,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date."}],"balance_after":18118,"derivative":{"exercise_price":3.31,"expiration_date":"2032-06-07","underlying":"Common Stock","underlying_shares":18118},"source":{"system":"sec-edgar","filing":"0000899243-22-021893","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850838/000089924322021893/doc4.xml","form_type":"4"}},{"id":2261661,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-20T23:30:38.000Z","date":"2022-05-19","kind":"grant","acquired":true,"shares":20500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full upon the earlier to occur of (i) the first anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date."}],"balance_after":20500,"derivative":{"exercise_price":29.02,"expiration_date":"2032-05-18","underlying":"Common Stock","underlying_shares":20500},"source":{"system":"sec-edgar","filing":"0001209191-22-031178","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000120919122031178/doc4.xml","form_type":"4"}},{"id":2657004,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2021-06-23T21:19:25.000Z","date":"2021-06-22","kind":"grant","acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in full on the one year anniversary of the date of grant."}],"balance_after":23000,"derivative":{"exercise_price":21.54,"expiration_date":"2031-06-21","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001209191-21-042788","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000120919121042788/doc4.xml","form_type":"4"}},{"id":2794431,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-12T02:47:59.000Z","date":"2021-03-11","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in substantially equal monthly installments over three years, commencing on March 17, 2021, subject to the Reporting Person's continued service with the Issuer through each vest date."}],"balance_after":40000,"derivative":{"exercise_price":19,"expiration_date":"2031-03-10","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-21-020029","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000120919121020029/doc4.xml","form_type":"4"}},{"id":2908134,"issuer":{"id":6276,"kind":"organization","name":"Coherus Oncology, Inc."},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-13T21:29:06.000Z","date":"2021-01-11","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2021, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":20000,"derivative":{"exercise_price":17.58,"expiration_date":"2031-01-11","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001567619-21-000987","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000156761921000987/doc1.xml","form_type":"4"}},{"id":3098415,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2020-06-26T20:10:38.000Z","date":"2020-06-24","kind":"grant","acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in full on the one year anniversary of the date of grant."}],"balance_after":23000,"derivative":{"exercise_price":17.97,"expiration_date":"2030-06-23","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001209191-20-039074","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000120919120039074/doc4.xml","form_type":"4"}},{"id":3100771,"issuer":{"id":6276,"kind":"organization","name":"Coherus Oncology, Inc."},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-24T20:55:07.000Z","date":"2020-06-22","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares underlying this option are vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":12.37,"expiration_date":"2029-01-11","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001567619-20-012534","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000156761920012534/doc1.xml","form_type":"4"}},{"id":3100770,"issuer":{"id":6276,"kind":"organization","name":"Coherus Oncology, Inc."},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-24T20:55:07.000Z","date":"2020-06-22","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares underlying this option are vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":10.05,"expiration_date":"2028-02-01","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001567619-20-012534","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000156761920012534/doc1.xml","form_type":"4"}},{"id":3100769,"issuer":{"id":6276,"kind":"organization","name":"Coherus Oncology, Inc."},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-24T20:55:07.000Z","date":"2020-06-22","kind":"exercise","acquired":false,"shares":14997,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares underlying this option are vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":2.5005,"expiration_date":"2024-06-30","underlying":"Common Stock","underlying_shares":14997},"source":{"system":"sec-edgar","filing":"0001567619-20-012534","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000156761920012534/doc1.xml","form_type":"4"}},{"id":3100768,"issuer":{"id":6276,"kind":"organization","name":"Coherus Oncology, Inc."},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.0001 par value","published_at":"2020-06-24T20:55:07.000Z","date":"2020-06-22","kind":"sale","acquired":false,"shares":54997,"price":17.5784,"value":966759.2648,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction was executed in multiple trades in prices ranging from $17.43 to $17.71, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001567619-20-012534","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000156761920012534/doc1.xml","form_type":"4"}},{"id":3100767,"issuer":{"id":6276,"kind":"organization","name":"Coherus Oncology, Inc."},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.0001 par value","published_at":"2020-06-24T20:55:07.000Z","date":"2020-06-22","kind":"exercise","acquired":true,"shares":20000,"price":12.37,"value":247400.0,"ownership":{"direct":true},"balance_after":54997,"source":{"system":"sec-edgar","filing":"0001567619-20-012534","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000156761920012534/doc1.xml","form_type":"4"}},{"id":3100766,"issuer":{"id":6276,"kind":"organization","name":"Coherus Oncology, Inc."},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.0001 par value","published_at":"2020-06-24T20:55:07.000Z","date":"2020-06-22","kind":"exercise","acquired":true,"shares":20000,"price":10.05,"value":201000.0,"ownership":{"direct":true},"balance_after":34997,"source":{"system":"sec-edgar","filing":"0001567619-20-012534","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000156761920012534/doc1.xml","form_type":"4"}},{"id":3100765,"issuer":{"id":6276,"kind":"organization","name":"Coherus Oncology, Inc."},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.0001 par value","published_at":"2020-06-24T20:55:07.000Z","date":"2020-06-22","kind":"exercise","acquired":true,"shares":14997,"price":2.5005,"value":37499.9985,"ownership":{"direct":true},"balance_after":14997,"source":{"system":"sec-edgar","filing":"0001567619-20-012534","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000156761920012534/doc1.xml","form_type":"4"}},{"id":3103014,"issuer":{"id":11664,"kind":"organization","name":"ALIMERA SCIENCES INC","symbol":"ALIM"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-22T20:18:59.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":3333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in equal monthly installments over 12 months starting one month after the grant date (June 18, 2020), provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date."}],"balance_after":3333,"derivative":{"exercise_price":6.7,"expiration_date":"2030-06-17","underlying":"Common Stock","underlying_shares":3333},"source":{"system":"sec-edgar","filing":"0001267602-20-000093","document":"wf-form4_159285712000024.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000126760220000093/wf-form4_159285712000024.xml","form_type":"4"}},{"id":3311489,"issuer":{"id":6276,"kind":"organization","name":"Coherus Oncology, Inc."},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-14T22:54:49.000Z","date":"2020-01-10","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2020, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":20000,"derivative":{"exercise_price":17.73,"expiration_date":"2030-01-10","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001567619-20-001047","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000156761920001047/doc1.xml","form_type":"4"}},{"id":3476849,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2019-06-27T20:10:57.000Z","date":"2019-06-25","kind":"grant","acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in full on the one year anniversary of the date of grant."}],"balance_after":13000,"derivative":{"exercise_price":19.55,"expiration_date":"2029-06-24","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001209191-19-039245","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000120919119039245/doc4.xml","form_type":"4"}},{"id":3482355,"issuer":{"id":11664,"kind":"organization","name":"ALIMERA SCIENCES INC","symbol":"ALIM"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-20T20:21:51.000Z","date":"2019-06-19","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in equal monthly installments over 12 months starting one month after the grant date (June 19, 2019), provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date."}],"balance_after":50000,"derivative":{"exercise_price":0.92,"expiration_date":"2029-06-18","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001267602-19-000087","document":"wf-form4_156106209699552.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000126760219000087/wf-form4_156106209699552.xml","form_type":"4"}},{"id":3682560,"issuer":{"id":6276,"kind":"organization","name":"Coherus Oncology, Inc."},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-30T21:08:13.000Z","date":"2019-01-11","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 11, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":20000,"derivative":{"exercise_price":12.37,"expiration_date":"2029-01-11","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-19-002192","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000089924319002192/doc4.xml","form_type":"4"}},{"id":3770503,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2018-11-08T19:18:06.000Z","date":"2018-11-06","kind":"grant","acquired":true,"shares":7583,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in full on the one year anniversary of the date of grant."}],"balance_after":7583,"derivative":{"exercise_price":11.55,"expiration_date":"2028-11-05","underlying":"Common Stock","underlying_shares":7583},"source":{"system":"sec-edgar","filing":"0001209191-18-057721","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000120919118057721/doc4.xml","form_type":"4"}},{"id":3770502,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2018-11-08T19:18:06.000Z","date":"2018-11-06","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in three equal annual installments commencing on the one year anniversary of the date of grant."}],"balance_after":30000,"derivative":{"exercise_price":11.55,"expiration_date":"2028-11-05","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-18-057721","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000120919118057721/doc4.xml","form_type":"4"}},{"id":3885995,"issuer":{"id":11664,"kind":"organization","name":"ALIMERA SCIENCES INC","symbol":"ALIM"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-06-21T20:31:12.000Z","date":"2018-06-19","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable in equal monthly installments over 12 months starting one month after the grant date, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date."}],"balance_after":40000,"derivative":{"exercise_price":0.86,"expiration_date":"2028-06-18","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001267602-18-000087","document":"wf-form4_152961305232435.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000126760218000087/wf-form4_152961305232435.xml","form_type":"4"}},{"id":4076098,"issuer":{"id":6276,"kind":"organization","name":"Coherus Oncology, Inc."},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-02-05T21:07:45.000Z","date":"2018-02-01","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":20000,"derivative":{"exercise_price":10.05,"expiration_date":"2028-02-01","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-18-002889","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000089924318002889/doc4.xml","form_type":"4"}},{"id":4311591,"issuer":{"id":6276,"kind":"organization","name":"Coherus Oncology, Inc."},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-19T20:06:47.000Z","date":"2017-05-17","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from May 17, 2017, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":20000,"derivative":{"exercise_price":23.8,"expiration_date":"2027-05-17","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-17-013898","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000089924317013898/doc4.xml","form_type":"4"}},{"id":4325952,"issuer":{"id":152369,"kind":"organization","name":"NOVELION THERAPEUTICS INC.","symbol":"NVLNF"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2017-05-11T16:02:57.000Z","date":"2017-05-09","kind":"exercise","acquired":false,"shares":6632,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one common share."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"33.34% of the grant vested on May 9, 2017. Subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer or one of its affiliates, 33.33% of the grant will vest on May 9, 2018 and 33.33% of the grant will vest on May 9, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"33.34% of the grant vested on May 9, 2017. Subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer or one of its affiliates, 33.33% of the grant will vest on May 9, 2018 and 33.33% of the grant will vest on May 9, 2019."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016."}],"balance_after":13264,"derivative":{"underlying":"Common Shares","underlying_shares":6632},"source":{"system":"sec-edgar","filing":"0001104659-17-031894","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/827809/000110465917031894/a4.xml","form_type":"4"}},{"id":4325951,"issuer":{"id":152369,"kind":"organization","name":"NOVELION THERAPEUTICS INC.","symbol":"NVLNF"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2017-05-11T16:02:57.000Z","date":"2017-05-09","kind":"tax_withholding","acquired":false,"shares":2248,"price":9.42,"value":21176.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The shares reported as disposed were withheld by the Issuer to satisfy tax withholding obligations of the Reporting Person."}],"balance_after":4384,"source":{"system":"sec-edgar","filing":"0001104659-17-031894","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/827809/000110465917031894/a4.xml","form_type":"4"}},{"id":4325950,"issuer":{"id":152369,"kind":"organization","name":"NOVELION THERAPEUTICS INC.","symbol":"NVLNF"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2017-05-11T16:02:57.000Z","date":"2017-05-09","kind":"exercise","acquired":true,"shares":6632,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one common share."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016."}],"balance_after":6632,"source":{"system":"sec-edgar","filing":"0001104659-17-031894","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827809/000110465917031894/a4.xml","form_type":"4"}},{"id":4512130,"issuer":{"id":152369,"kind":"organization","name":"NOVELION THERAPEUTICS INC.","symbol":"NVLNF"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2016-12-27T16:06:32.000Z","date":"2016-12-22","kind":"grant","acquired":true,"shares":323520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The common shares underlying this stock option award will vest in three equal installments on December 22, 2017, December 22, 2018 and December 22, 2019, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer or one its affiliates."}],"balance_after":323520,"derivative":{"exercise_price":8.65,"expiration_date":"2026-12-22","underlying":"Common Shares","underlying_shares":323520},"source":{"system":"sec-edgar","filing":"0001104659-16-163875","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827809/000110465916163875/a4.xml","form_type":"4"}},{"id":4537923,"issuer":{"id":152369,"kind":"organization","name":"NOVELION THERAPEUTICS INC.","symbol":"NVLNF"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2016-12-01T16:05:36.000Z","date":"2016-11-29","kind":"grant","acquired":true,"shares":99483,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one common share of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Agreement and Plan of Merger, dated as of June 14, 2016, by and among the Issuer, Aegerion Pharmaceuticals, Inc. (\"Aegerion\") and Isotope Acquisition Corp. (\"Isotope\"), pursuant to which Isotope was merged with and into Aegerion, effective on November 29, 2016, each restricted stock unit with respect to common stock of Aegerion (\"Aegerion RSU\") that was outstanding as of immediately prior to the effective time of the merger was exchanged for a restricted stock unit with respect to a number of common shares of the Issuer (\"Issuer RSU\") equal to the product obtained by multiplying (i) the total number of shares of common stock of Aegerion subject to the Aegerion RSU immediately prior to the effective time of the merger by (ii) the exchange ratio of 1.0256."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each Issuer RSU is subject to the same terms and conditions applicable to the corresponding Aegerion RSU and the agreements evidencing grant of the Aegerion RSUs thereunder, including vesting terms, but excluding any terms that are rendered inoperative solely by reason of the merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units will vest in three annual installments, with 33.34% of the units vesting on May 9, 2017, 33.33% of the units vesting on May 9, 2018 and 33.33% of the units vesting on May 9, 2019, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer or any of its subsidiaries."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units will vest in three annual installments, with 33.34% of the units vesting on May 9, 2017, 33.33% of the units vesting on May 9, 2018 and 33.33% of the units vesting on May 9, 2019, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer or any of its subsidiaries."}],"balance_after":99483,"derivative":{"underlying":"Common Shares","underlying_shares":99483},"source":{"system":"sec-edgar","filing":"0001104659-16-160109","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827809/000110465916160109/a4.xml","form_type":"4"}},{"id":4538662,"issuer":{"id":180735,"kind":"organization","name":"Aegerion Pharmaceuticals, Inc.","symbol":"AEGR"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2016-12-01T00:50:05.000Z","date":"2016-11-29","kind":"disposition_to_issuer","acquired":false,"shares":97000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represented a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, each restricted stock unit with respect to common stock of the Issuer (\"Aegerion RSU\") that was outstanding as of immediately prior to the effective time of the merger was exchanged for a restricted stock unit  (\"Novelion RSU\") with respect to a number of common shares of Novelion equal to the product obtained by multiplying (i) the total number of shares of common stock of the Issuer subject to the Aegerion RSU immediately prior to the effective time of the merger by (ii) the Exchange Ratio. Each Novelion RSU is subject to the same terms and conditions applicable to the corresponding Aegerion RSU and the agreements evidencing grant of the Aegerion RSUs thereunder, including vesting terms, but excluding any terms that are rendered inoperative solely by reason of the merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The restricted stock units were to vest in three annual installments, with 33.34% of the units scheduled to vest on May 9, 2017, 33.33% of the units scheduled to vest on May 9, 2018 and 33.33% of the units scheduled to vest on May 9, 2019, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The restricted stock units were to vest in three annual installments, with 33.34% of the units scheduled to vest on May 9, 2017, 33.33% of the units scheduled to vest on May 9, 2018 and 33.33% of the units scheduled to vest on May 9, 2019, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":97000},"source":{"system":"sec-edgar","filing":"0001104659-16-159826","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000110465916159826/a4.xml","form_type":"4"}},{"id":4538661,"issuer":{"id":180735,"kind":"organization","name":"Aegerion Pharmaceuticals, Inc.","symbol":"AEGR"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2016-12-01T00:50:05.000Z","date":"2016-11-29","kind":"disposition_to_issuer","acquired":false,"shares":194000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of June 14, 2016, by and among the Issuer, QLT Inc. (\"QLT\") and Isotope Acquisition Corp. (\"Isotope\"), pursuant to which Isotope was merged with and into the Issuer, effective on November 29, 2016, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 (the \"Exchange Ratio\") by (ii) $1.83, the closing price of a common share of QLT on November 28, 2016) was cancelled without any payment or other consideration therefor. Following completion of the merger, QLT was renamed \"Novelion Therapeutics Inc.\" (\"Novelion\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares of common stock underlying this stock option award were to vest on May 9, 2017. The remaining 75% of the shares of common stock underlying this stock option award were to vest thereafter in equal monthly installments through May 9, 2020, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer."}],"balance_after":0,"derivative":{"exercise_price":2.46,"expiration_date":"2026-05-09","underlying":"Common Stock","underlying_shares":194000},"source":{"system":"sec-edgar","filing":"0001104659-16-159826","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000110465916159826/a4.xml","form_type":"4"}},{"id":4538660,"issuer":{"id":180735,"kind":"organization","name":"Aegerion Pharmaceuticals, Inc.","symbol":"AEGR"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2016-12-01T00:50:05.000Z","date":"2016-11-29","kind":"disposition_to_issuer","acquired":false,"shares":600000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of June 14, 2016, by and among the Issuer, QLT Inc. (\"QLT\") and Isotope Acquisition Corp. (\"Isotope\"), pursuant to which Isotope was merged with and into the Issuer, effective on November 29, 2016, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 (the \"Exchange Ratio\") by (ii) $1.83, the closing price of a common share of QLT on November 28, 2016) was cancelled without any payment or other consideration therefor. Following completion of the merger, QLT was renamed \"Novelion Therapeutics Inc.\" (\"Novelion\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares of common stock underlying this stock option award were to vest on January 7, 2017. The remaining 75% of the shares of common stock underlying this stock option award were to vest thereafter in equal monthly installments through January 7, 2020, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer."}],"balance_after":0,"derivative":{"exercise_price":8.65,"expiration_date":"2026-01-07","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001104659-16-159826","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410289/000110465916159826/a4.xml","form_type":"4"}},{"id":498684,"issuer":{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Option (right to buy)","published_at":"2011-12-16T23:23:44.000Z","date":"2011-12-14","kind":"exercise","acquired":false,"shares":53201,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3."}],"balance_after":0,"derivative":{"exercise_price":53.625,"exercise_date":"2005-02-15","expiration_date":"2012-02-14","underlying":"Common Shares","underlying_shares":53201},"source":{"system":"sec-edgar","filing":"0001179110-11-016829","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":29,"url":"https://www.sec.gov/Archives/edgar/data/1800/000117911011016829/edgar.xml","form_type":"4"}},{"id":498683,"issuer":{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common shares without par value","published_at":"2011-12-16T23:23:44.000Z","date":"2011-12-14","kind":"sale","acquired":false,"shares":500,"price":54.46,"value":27230.0,"ownership":{"direct":true},"balance_after":119342,"source":{"system":"sec-edgar","filing":"0001179110-11-016829","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1800/000117911011016829/edgar.xml","form_type":"4"}},{"id":498682,"issuer":{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common shares without par value","published_at":"2011-12-16T23:23:44.000Z","date":"2011-12-14","kind":"sale","acquired":false,"shares":2781,"price":54.445,"value":151411.545,"ownership":{"direct":true},"balance_after":119842,"source":{"system":"sec-edgar","filing":"0001179110-11-016829","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1800/000117911011016829/edgar.xml","form_type":"4"}},{"id":498681,"issuer":{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common shares without par value","published_at":"2011-12-16T23:23:44.000Z","date":"2011-12-14","kind":"sale","acquired":false,"shares":3200,"price":54.44,"value":174208.0,"ownership":{"direct":true},"balance_after":122623,"source":{"system":"sec-edgar","filing":"0001179110-11-016829","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1800/000117911011016829/edgar.xml","form_type":"4"}},{"id":498680,"issuer":{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common shares without par value","published_at":"2011-12-16T23:23:44.000Z","date":"2011-12-14","kind":"sale","acquired":false,"shares":2700,"price":54.43,"value":146961.0,"ownership":{"direct":true},"balance_after":125823,"source":{"system":"sec-edgar","filing":"0001179110-11-016829","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1800/000117911011016829/edgar.xml","form_type":"4"}},{"id":498679,"issuer":{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common shares without par value","published_at":"2011-12-16T23:23:44.000Z","date":"2011-12-14","kind":"sale","acquired":false,"shares":212,"price":54.425,"value":11538.1,"ownership":{"direct":true},"balance_after":128523,"source":{"system":"sec-edgar","filing":"0001179110-11-016829","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1800/000117911011016829/edgar.xml","form_type":"4"}},{"id":498678,"issuer":{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common shares without par value","published_at":"2011-12-16T23:23:44.000Z","date":"2011-12-14","kind":"sale","acquired":false,"shares":2488,"price":54.42,"value":135396.96,"ownership":{"direct":true},"balance_after":128735,"source":{"system":"sec-edgar","filing":"0001179110-11-016829","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1800/000117911011016829/edgar.xml","form_type":"4"}},{"id":498677,"issuer":{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common shares without par value","published_at":"2011-12-16T23:23:44.000Z","date":"2011-12-14","kind":"sale","acquired":false,"shares":5275,"price":54.41,"value":287012.75,"ownership":{"direct":true},"balance_after":131223,"source":{"system":"sec-edgar","filing":"0001179110-11-016829","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1800/000117911011016829/edgar.xml","form_type":"4"}},{"id":498676,"issuer":{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common shares without par value","published_at":"2011-12-16T23:23:44.000Z","date":"2011-12-14","kind":"sale","acquired":false,"shares":2300,"price":54.405,"value":125131.5,"ownership":{"direct":true},"balance_after":136498,"source":{"system":"sec-edgar","filing":"0001179110-11-016829","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1800/000117911011016829/edgar.xml","form_type":"4"}},{"id":498675,"issuer":{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common shares without par value","published_at":"2011-12-16T23:23:44.000Z","date":"2011-12-14","kind":"sale","acquired":false,"shares":4500,"price":54.4,"value":244800.0,"ownership":{"direct":true},"balance_after":138798,"source":{"system":"sec-edgar","filing":"0001179110-11-016829","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1800/000117911011016829/edgar.xml","form_type":"4"}},{"id":498674,"issuer":{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common shares without par value","published_at":"2011-12-16T23:23:44.000Z","date":"2011-12-14","kind":"sale","acquired":false,"shares":3700,"price":54.395,"value":201261.5,"ownership":{"direct":true},"balance_after":143298,"source":{"system":"sec-edgar","filing":"0001179110-11-016829","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1800/000117911011016829/edgar.xml","form_type":"4"}},{"id":498673,"issuer":{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common shares without par value","published_at":"2011-12-16T23:23:44.000Z","date":"2011-12-14","kind":"sale","acquired":false,"shares":1900,"price":54.39,"value":103341.0,"ownership":{"direct":true},"balance_after":146998,"source":{"system":"sec-edgar","filing":"0001179110-11-016829","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1800/000117911011016829/edgar.xml","form_type":"4"}},{"id":498672,"issuer":{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common shares without par value","published_at":"2011-12-16T23:23:44.000Z","date":"2011-12-14","kind":"sale","acquired":false,"shares":100,"price":54.3875,"value":5438.75,"ownership":{"direct":true},"balance_after":148898,"source":{"system":"sec-edgar","filing":"0001179110-11-016829","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1800/000117911011016829/edgar.xml","form_type":"4"}},{"id":498671,"issuer":{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common shares without par value","published_at":"2011-12-16T23:23:44.000Z","date":"2011-12-14","kind":"sale","acquired":false,"shares":1600,"price":54.385,"value":87016.0,"ownership":{"direct":true},"balance_after":148998,"source":{"system":"sec-edgar","filing":"0001179110-11-016829","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1800/000117911011016829/edgar.xml","form_type":"4"}},{"id":498670,"issuer":{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common shares without par value","published_at":"2011-12-16T23:23:44.000Z","date":"2011-12-14","kind":"sale","acquired":false,"shares":5195,"price":54.38,"value":282504.1,"ownership":{"direct":true},"balance_after":150598,"source":{"system":"sec-edgar","filing":"0001179110-11-016829","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1800/000117911011016829/edgar.xml","form_type":"4"}},{"id":498669,"issuer":{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common shares without par value","published_at":"2011-12-16T23:23:44.000Z","date":"2011-12-14","kind":"sale","acquired":false,"shares":5500,"price":54.375,"value":299062.5,"ownership":{"direct":true},"balance_after":155793,"source":{"system":"sec-edgar","filing":"0001179110-11-016829","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1800/000117911011016829/edgar.xml","form_type":"4"}},{"id":498668,"issuer":{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common shares without par value","published_at":"2011-12-16T23:23:44.000Z","date":"2011-12-14","kind":"sale","acquired":false,"shares":900,"price":54.37,"value":48933.0,"ownership":{"direct":true},"balance_after":161293,"source":{"system":"sec-edgar","filing":"0001179110-11-016829","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1800/000117911011016829/edgar.xml","form_type":"4"}},{"id":498667,"issuer":{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common shares without par value","published_at":"2011-12-16T23:23:44.000Z","date":"2011-12-14","kind":"sale","acquired":false,"shares":100,"price":54.365,"value":5436.5,"ownership":{"direct":true},"balance_after":162193,"source":{"system":"sec-edgar","filing":"0001179110-11-016829","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1800/000117911011016829/edgar.xml","form_type":"4"}},{"id":498666,"issuer":{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common shares without par value","published_at":"2011-12-16T23:23:44.000Z","date":"2011-12-14","kind":"sale","acquired":false,"shares":2100,"price":54.36,"value":114156.0,"ownership":{"direct":true},"balance_after":162293,"source":{"system":"sec-edgar","filing":"0001179110-11-016829","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1800/000117911011016829/edgar.xml","form_type":"4"}},{"id":498665,"issuer":{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common shares without par value","published_at":"2011-12-16T23:23:44.000Z","date":"2011-12-14","kind":"sale","acquired":false,"shares":2100,"price":54.355,"value":114145.5,"ownership":{"direct":true},"balance_after":164393,"source":{"system":"sec-edgar","filing":"0001179110-11-016829","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1800/000117911011016829/edgar.xml","form_type":"4"}},{"id":498664,"issuer":{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common shares without par value","published_at":"2011-12-16T23:23:44.000Z","date":"2011-12-14","kind":"sale","acquired":false,"shares":1550,"price":54.35,"value":84242.5,"ownership":{"direct":true},"balance_after":166493,"source":{"system":"sec-edgar","filing":"0001179110-11-016829","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1800/000117911011016829/edgar.xml","form_type":"4"}},{"id":498663,"issuer":{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common shares without par value","published_at":"2011-12-16T23:23:44.000Z","date":"2011-12-14","kind":"sale","acquired":false,"shares":900,"price":54.345,"value":48910.5,"ownership":{"direct":true},"balance_after":168043,"source":{"system":"sec-edgar","filing":"0001179110-11-016829","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1800/000117911011016829/edgar.xml","form_type":"4"}},{"id":498662,"issuer":{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common shares without par value","published_at":"2011-12-16T23:23:44.000Z","date":"2011-12-14","kind":"sale","acquired":false,"shares":100,"price":54.34,"value":5434.0,"ownership":{"direct":true},"balance_after":168943,"source":{"system":"sec-edgar","filing":"0001179110-11-016829","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1800/000117911011016829/edgar.xml","form_type":"4"}},{"id":498661,"issuer":{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common shares without par value","published_at":"2011-12-16T23:23:44.000Z","date":"2011-12-14","kind":"sale","acquired":false,"shares":200,"price":54.335,"value":10867.0,"ownership":{"direct":true},"balance_after":169043,"source":{"system":"sec-edgar","filing":"0001179110-11-016829","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1800/000117911011016829/edgar.xml","form_type":"4"}},{"id":498660,"issuer":{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT"},"owners":[{"id":16829,"kind":"person","name":"Szela Mary T","position":1,"cik":"0001410289","reported_name":"Szela Mary T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common shares without par value","published_at":"2011-12-16T23:23:44.000Z","date":"2011-12-14","kind":"sale","acquired":false,"shares":2500,"price":54.33,"value":135825.0,"ownership":{"direct":true},"balance_after":169243,"source":{"system":"sec-edgar","filing":"0001179110-11-016829","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1800/000117911011016829/edgar.xml","form_type":"4"}}],"next_cursor":"2011-12-16T23:23:44.000000Z,498660"}